Q-omics provides the consensus-scored FOXC1 profile across patient tissues and cancer cell-line models. FOXC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FOXC1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FOXC1 RNA expression shows 18,178 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where FOXC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXC1 survival associations across molecular data types. FOXC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXC1 RNA expression–survival associations across cancer types. High FOXC1 expression shows unfavorable associations in UVM, PAAD, COAD, DLBC and LGG, but favorable associations in LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FOXC1 RNA expression.
This table summarizes FOXC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXC1 shows lower tumor expression in KIRC, KICH and BRCA and higher tumor expression in STAD, LIHC and COAD. The KIRC box plot shows higher FOXC1 RNA expression in normal versus tumor tissue (log2 FC = −2.016, t-test p < 0.001).
This table shows molecular features associated with FOXC1 in patient tissues and cancer cell lines. In patient samples, FOXC1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
